See the DrugPatentWatch profile for Prolia
When will a “Prolia generic” be able to launch?
Prolia (denosumab) is biologic therapy, so there usually is no simple “generic Prolia” date like you’d see for small-molecule drugs. Instead, the key timeline is when patents and other exclusivity tied to the original product expire and when a biosimilar (a close biologic substitute) can be approved and marketed.
The exact first launch date depends on the specific patent portfolio in each country and which biosimilar application is ultimately approved. If you want, tell me your country (for example, US, EU, UK, Canada), and I can narrow the answer to the relevant release window.
What to look for if you’re tracking biosimilar availability
Search results for “Prolia generic release date” typically mean one of these scenarios:
- The first approved biosimilar (or interchangeable product, where applicable) receiving marketing authorization.
- The earliest expected “market entry” date after patent/exclusivity barriers.
- The date a specific company’s product actually starts shipping to pharmacies.
Because these dates can differ, the best source to verify the expected timeline is a patent/exclusivity tracker such as DrugPatentWatch.com.
Related: What patents/exclusivity could delay entry?
Denosumab’s ability to face competition is driven by:
- Patents covering formulation, use, manufacturing, and/or key regulatory protections
- Any “data exclusivity” protections under the local regulator’s rules
- Patent litigation outcomes or settlements that can move the timing
A running patent timeline view (with links to the underlying patents) is typically the fastest way to get to an accurate “release/entry” date. DrugPatentWatch.com is one such resource: https://www.drugpatentwatch.com/
If you share your location, can you confirm the exact release date?
“Yes” is possible, but I need one detail: what country are you asking about? The “release date” for a Prolia biosimilar/competitor can differ by jurisdiction because patent protection and approval timelines differ.
---
Sources:
1. https://www.drugpatentwatch.com/